15,651 results on '"RENAL cancer"'
Search Results
102. Applications of 3D Printing in the Abdomen and Pelvis
- Author
-
Chokshi, Shivum, Ballard, David H., Gupta, Rajul, Chadalavada, Seetharam C., Wake, Nicole, Rybicki, Frank J., editor, Morris, Jonathan M., editor, and Grant, Gerald T., editor
- Published
- 2024
- Full Text
- View/download PDF
103. High Expression of Mannosyl-Oligosaccharide Glucosidase Is Associated with Poor Prognosis of Renal Clear Cell Carcinoma
- Author
-
Dang, Thanh Nghia, Nguyen, Minh Nam, Magjarević, Ratko, Series Editor, Ładyżyński, Piotr, Associate Editor, Ibrahim, Fatimah, Associate Editor, Lackovic, Igor, Associate Editor, Rock, Emilio Sacristan, Associate Editor, Vo, Van Toi, editor, Nguyen, Thi-Hiep, editor, Vong, Binh Long, editor, Le, Ngoc Bich, editor, and Nguyen, Thanh Qua, editor
- Published
- 2024
- Full Text
- View/download PDF
104. 64Cu-GRIP B in Patients With Advanced Malignancies
- Author
-
National Cancer Institute (NCI), U.S. Army Medical Research Acquisition Activity, and Rahul Aggarwal, Principal Investigator
- Published
- 2023
105. HPI Effect in Robotic Urological Surgery on AKI
- Author
-
Sooyoung Cho, Assistant Professor
- Published
- 2023
106. Impact of Telemonitoring for the Management of Side Effects in Patients With Melanoma, Lung or Renal Cancer, Treated With Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy (MONITOR)
- Published
- 2023
107. A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
- Published
- 2023
108. Kidney Cancer Observational Protocol
- Author
-
Francesco Montorsi, Professor
- Published
- 2023
109. KIDNEY-PAGER: Analysis of Circulating Tumor DNA as a Biomarker in Renal Cancer - an Observational Trial (KIDNEY-PAGER)
- Published
- 2023
110. Video Education With Result Dependent dIsclosure (VERDI)
- Author
-
National Cancer Institute (NCI), National Human Genome Research Institute (NHGRI), and Huma Rana, MD, Principal Investigator
- Published
- 2023
111. A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
- Published
- 2023
112. NSAID Use After Robotic Partial Nephrectomy (No-PAIN)
- Author
-
Mark L. Gonzalgo, MD, PhD, Professor of Clinical
- Published
- 2023
113. Advanced Diffusion Imaging in Renal Cancer Patients
- Author
-
National Institutes of Health (NIH)
- Published
- 2023
114. Stereotactic Magnetic Resonance Guided Radiation Therapy
- Author
-
Jonathan Leeman, MD, Principal Investigator
- Published
- 2023
115. Prevalence and prognosis of malignancy in THSD7A-associated membranous nephropathy: a systematic literature review and clinical case study.
- Author
-
Xu, Qianqian, Li, Jiayi, Yang, Yue, Zhuo, Li, Gao, Hongmei, Jiang, Shimin, and Li, Wenge
- Subjects
- *
LITERATURE reviews , *SMALL cell lung cancer , *PROGNOSIS , *KIDNEY diseases , *RENAL cancer , *BK virus - Abstract
This study aims to investigate the incidence and prognosis of malignancy in individuals with thrombospondin type-1 domain-containing 7A (THSD7A)-associated membranous nephropathy (MN). First, we performed a systematic literature review of prevalence of malignancy in THSD7A-associated MN. Then, we conducted a retrospective analysis of 454 patients diagnosed with MN through renal biopsy at our hospital between January 2016 and December 2020. We assessed the presence of serum anti-THSD7A antibodies and performed immunohistochemical staining of renal tissue for THSD7A. Subsequently, we followed patients with THSD7A-associated MN for a minimum of 3–5 years, collecting their clinical, pathological characteristics, and prognosis. Additionally, we conducted a literature review on patients with THSD7A-associated MN in conjunction with malignancy. We identified a total of nine articles containing comprehensive data on THSD7A-associated MN and malignancy. Among 235 patients with THSD7A-positive MN, 36 individuals had concurrent malignancies, resulting in a malignancy prevalence of 13.3% (95% CI: 8.9–17.7%). In our center, we followed up with 15 patients diagnosed with THSD7A-associated MN and observed three cases of concomitant tumors: two cases of lung adenocarcinoma and one case of small cell lung cancer with multiple metastases. The prevalence of malignancy in our cohort was 20%. Notably, we detected positive THSD7A staining in both renal and lung cancer tissues in one patient with small cell lung cancer. Patients with THSD7A-associated MN should undergo vigilant follow-up assessments, with a particular focus on actively seeking potential tumorigenic lesions to prevent misdiagnosis or oversight. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
116. Same-day discharge after percutaneous renal cryoablation and its effect on 30 day hospital re-admission rates and post-procedural complications.
- Author
-
Akinduro, Oluwanifemi Glory, Babar, Tarik, Allen, David M., Li, Mei, Salei, Aliaksei, Huang, Junjian, and Gunn, Andrew J.
- Abstract
The purpose of this study is to identify if the local institutional shift from routine overnight observation to same-day discharge following percutaneous cryoablation (PCA) of renal tumors increases 30 day re-admission rates or serious adverse events (AEs). This retrospective study included 133 adult patients. PCA patients in calendar years 2018-2019 were routinely observed overnight in the hospital, comprising the control group (Group A). PCA patients in calendar years 2021-2022 were routinely discharged the same day, comprising the test group (Group B). Relevant demographic information, tumor characteristics, technical outcomes, and clinical outcomes were recorded. 15 patients (11.3 %) from the total cohort were re-admitted to the hospital within 30 days of PCA for any reason. Seven patients (10.4 %) and eight patients (12.1 %) were re-admitted for any reason within 30 days in Group A and Group B, respectively, with no difference between the two groups (p = 0.76). Nine patients (6.8 %) from the total cohort were re-admitted to the hospital within 30 days for a diagnosis secondary to the procedure. Four patients (6 %) and five patients (7.6 %) were re-admitted within 30 days for reasons related to PCA in Group A and Group B, respectively, with no significant difference between the groups (p = 0.71). Eight patients (12 %) and four patients (6 %) had major AEs following PCA in Group A and Group B, respectively, with no difference between the two groups (p = 0.43). Overall, the change in post-procedural care after PCA did not have a deleterious effect on 30 day re-admission rates or rates of major AEs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
117. NMRK2 is an efficient diagnostic indicator for Xp11.2 translocation renal cell carcinoma.
- Author
-
Feng, Huayi, Cao, Shouqing, Fu, Shihui, Liu, Junxiao, Gao, Yu, Dong, Zhouhuan, Cai, Tianwei, Wen, Lequan, Xiong, Zhuang, Li, Shangwei, Zhang, Xu, Ma, Xin, and Li, Xiubin
- Subjects
RENAL cell carcinoma ,FLUORESCENCE in situ hybridization ,RENAL cancer ,CHIMERIC proteins ,SURGICAL excision - Abstract
Xp11.2 translocation renal cell carcinomas (tRCC) are a rare and highly malignant type of renal cancer, lacking efficient diagnostic indicators and therapeutic targets. Through the analysis of public databases and our cohort, we identified NMRK2 as a potential diagnostic marker for distinguishing Xp11.2 tRCC from kidney renal clear cell carcinoma (KIRC) and kidney renal papillary cell carcinoma (KIRP) due to its specific upregulation in Xp11.2 tRCC tissues. Mechanistically, we discovered that TFE3 fusion protein binds to the promoter of the NMRK2 gene, leading to its upregulation. Importantly, we established RNA‐ and protein‐based diagnostic methods for identifying Xp11.2 tRCC based on NMRK2 expression levels, and the diagnostic performance of our methods was comparable to a dual‐color break‐apart fluorescence in situ hybridization assay. Moreover, we successfully identified fresh Xp11.2 tRCC tissues after surgical excision using our diagnostic methods and established an immortalized Xp11.2 tRCC cell line for further research purposes. Functional studies revealed that NMRK2 promotes the progression of Xp11.2 tRCC by upregulating the NAD+/NADH ratio, and supplementation with β‐nicotinamide mononucleotide (NMN) or nicotinamide riboside chloride (NR), effectively rescued the phenotypes induced by the knockdown of NMRK2 in Xp11.2 tRCC. Taken together, these data introduce a new diagnostic indicator capable of accurately distinguishing Xp11.2 tRCC and highlight the possibility of developing novel targeted therapeutics. © 2024 The Pathological Society of Great Britain and Ireland. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
118. Integrated mendelian randomization analyses highlight AFF3 as a novel eQTL-mediated susceptibility gene in renal cancer and its potential mechanisms
- Author
-
Qiming Wang, Shaopeng Chen, Gang Wang, Tielong Zhang, and Yulong Gao
- Subjects
Mendelian randomization ,eQTL ,SMR ,AFF3 ,Renal cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Backgrounds A growing number of expression quantitative trait loci (eQTLs) have been found to be linked with tumorigenesis. In this article, we employed integrated Mendelian randomization (MR) analyses to identify novel susceptibility genes in renal cancer (RC) and reveal their potential mechanisms. Methods Two-sample MR analyses were performed to infer causal relationships between eQTLs, metabolites, and RC risks through the “TwoSampleMR” R package. Sensitivity analyses, such as heterogeneity, pleiotropy, and leave-one-out analysis, were used to assess the stability of our outcomes. Summary-data-based MR (SMR) analyses were used to verify the causal relationships among cis-eQTLs and RC risks via the SMR 1.3.1 software. Results Our results provided the first evidence for AFF3 eQTL elevating RC risks, suggesting its oncogenic roles (IVW method; odds ratio (OR) = 1.0005; 95% confidence interval (CI) = 1.0001–1.0010; P = 0.0285; heterogeneity = 0.9588; pleiotropy = 0.8397). Further SMR analysis validated the causal relationships among AFF3 cis-eQTLs and RC risks (P
- Published
- 2024
- Full Text
- View/download PDF
119. Prognostic factors and treatment impact on overall survival in patients with renal neuroendocrine tumour
- Author
-
Olamide O. Omidele, Christopher Connors, Nikhil Wainganker, Ketan Badani, John Sfakianos, Reza Mehrazin, and Isuru Jayaratna
- Subjects
kidney tumours ,neuroendocrine carcinoma ,partial nephrectomy ,radical nephrectomy ,renal cancer ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Abstract Background Renal neuroendocrine neoplasms (R‐NEN) are exceptionally rare tumours characterized by high mortality rates. Objective The objective of this study is to analyse prognostic factors and treatment impact on overall survival in patients with R‐NEN. Design, setting and participants We identified all patients with R‐NEN in the National Cancer Database (NCDB) from 2004 to 2019 and identified prognostic factors for improved survival. Results and limitations Of 542 R‐NEN cases, 166 (31%) were neuroendocrine tumour grade 1 (NET‐G1), 14 (3%) were neuroendocrine tumour grade 2 (NET‐G2), 169 (31%) were neuroendocrine carcinoma (NEC‐NOS), 18 (3%) were large cell neuroendocrine carcinoma (LC‐NEC) and 175 (32%) were small cell neuroendocrine carcinoma (SC‐NEC). Median overall survival for all patients in the study was 44.88 months (SE, 4.265; 95% CI, 27.57–62.19). Median overall survival was 7.89 months (SE 0.67; 95% CI, 6.58–9.20) for patients without surgical intervention and 136.61 months (SE 16.44; 95% CI, 104.38–168.84, p
- Published
- 2024
- Full Text
- View/download PDF
120. Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastrophe
- Author
-
Hari K. Rachamala, Vijay S. Madamsetty, Ramcharan S. Angom, Naga M. Nakka, Shamit Kumar Dutta, Enfeng Wang, Debabrata Mukhopadhyay, and Krishnendu Pal
- Subjects
Renal cancer ,Radiation therapy ,mTOR ,Survivin ,Mitotic catastrophe ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Renal cell carcinoma (RCC) was historically considered to be less responsive to radiation therapy (RT) compared to other cancer indications. However, advancements in precision high-dose radiation delivery through single-fraction and multi-fraction stereotactic ablative radiotherapy (SABR) have led to better outcomes and reduced treatment-related toxicities, sparking renewed interest in using RT to treat RCC. Moreover, numerous studies have revealed that certain therapeutic agents including chemotherapies can increase the sensitivity of tumors to RT, leading to a growing interest in combining these treatments. Here, we developed a rational combination of two radiosensitizers in a tumor-targeted liposomal formulation for augmenting RT in RCC. The objective of this study is to assess the efficacy of a tumor-targeted liposomal formulation combining the mTOR inhibitor everolimus (E) with the survivin inhibitor YM155 (Y) in enhancing the sensitivity of RCC tumors to radiation. Experimental design We slightly modified our previously published tumor-targeted liposomal formulation to develop a rational combination of E and Y in a single liposomal formulation (EY-L) and assessed its efficacy in RCC cell lines in vitro and in RCC tumors in vivo. We further investigated how well EY-L sensitizes RCC cell lines and tumors toward radiation and explored the underlying mechanism of radiosensitization. Results EY-L outperformed the corresponding single drug-loaded formulations E-L and Y-L in terms of containing primary tumor growth and improving survival in an immunocompetent syngeneic mouse model of RCC. EY-L also exhibited significantly higher sensitization of RCC cells towards radiation in vitro than E-L and Y-L. Additionally, EY-L sensitized RCC tumors towards radiation therapy in xenograft and murine RCC models. EY-L mediated induction of mitotic catastrophe via downregulation of multiple cell cycle checkpoints and DNA damage repair pathways could be responsible for the augmentation of radiation therapy. Conclusion Taken together, our study demonstrated the efficacy of a strategic combination therapy in sensitizing RCC to radiation therapy via inhibition of DNA damage repair and a substantial increase in mitotic catastrophe. This combination therapy may find its use in the augmentation of radiation therapy during the treatment of RCC patients.
- Published
- 2024
- Full Text
- View/download PDF
121. Jolkinolide B induces reactive oxygen species accumulation and endoplasmic reticulum stress and inhibits MAPK and AKT signaling activation in renal cancer cells
- Author
-
Xuan Wu, Sijing Pan, Xiujuan Li, Jing Liu, Zhigang Wang, Yinghong Lei, and Qunchao Mei
- Subjects
renal cancer ,jolkinolide b ,ros ,endoplasmic reticulum stress ,mapk ,akt ,Medicine (General) ,R5-920 - Abstract
To investigate the impact of Jolkinolide B (JB) on renal cell carcinoma (RCC), we treated RCC cell lines with various concentrations of JB (0, 5, 25, 50 and 100 μM) for 24 hours and assessed cell viability using the cell counting kit-8 (CCK-8) analysis. Then, we examined JB’s effects on proliferation, migration, apoptosis, reactive oxygen species (ROS) accumulation, and endoplasmic reticulum (ER) stress through 5-ethynyl-2′-deoxyuridine (EdU) incorporation, transwell migration assays, flow cytometry, ROS level determination, and western blot assays. Furthermore, we investigated the potential mechanism using western blot. Our results showed that JB dose-dependently reduced cell viability in both 786-O and Caki1 cells. Additionally, JB at concentrations of 5, 25 and 50 μM decreased the number of EdU-positive and migrating cells in both cell lines. Additionally, these concentrations of JB increased apoptosis rates, relative protein expressions of cleaved caspase-3 and cleaved caspase-9, ROS levels, and relative protein expressions of C/EBP-homologous protein (CHOP) and activated transcription factor 4 (ATF4) in both 786-O and Caki1 cells. Mechanistically, treatment with all three concentrations of JB significantly downregulated phosphorylated p38 (p-p38)/p38, phosphorylated protein kinase B (p-AKT)/AKT and phosphorylated phosphatidylinositol-3-kinase (p-PI3K)/PI3K in a dose-dependent manner. In summary, JB inhibited proliferation and migration while promoting apoptosis, ROS accumulation, and ER stress in RCC cells, potentially through the inactivation of mitogen-activated protein kinase (MAPK) and AKT signaling pathways.
- Published
- 2024
- Full Text
- View/download PDF
122. Association between metabolic syndrome and kidney cancer risk: a prospective cohort study
- Author
-
Lin Wang, Han Du, Chao Sheng, Hongji Dai, and Kexin Chen
- Subjects
Metabolic syndrome ,Renal cancer ,Hypertension ,Central obesity ,Dyslipidemia ,Polygenic risk score ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
Abstract Background Kidney cancer has become known as a metabolic disease. However, there is limited evidence linking metabolic syndrome (MetS) with kidney cancer risk. This study aimed to investigate the association between MetS and its components and the risk of kidney cancer. Methods UK Biobank data was used in this study. MetS was defined as having three or more metabolic abnormalities, while pre-MetS was defined as the presence of one or two metabolic abnormalities. Hazard ratios (HRs) and 95% confidence intervals (CIs) for kidney cancer risk by MetS category were calculated using multivariable Cox proportional hazards models. Subgroup analyses were conducted for age, sex, BMI, smoking status and drinking status. The joint effects of MetS and genetic factors on kidney cancer risk were also analyzed. Results This study included 355,678 participants without cancer at recruitment. During a median follow-up of 11 years, 1203 participants developed kidney cancer. Compared to the metabolically healthy group, participants with pre-MetS (HR= 1.36, 95% CI: 1.06-1.74) or MetS (HR= 1. 70, 95% CI: 1.30-2.23) had a significantly greater risk of kidney cancer. This risk increased with the increasing number of MetS components (P for trend < 0.001). The combination of hypertension, dyslipidemia and central obesity contributed to the highest risk of kidney cancer (HR= 3.03, 95% CI: 1.91-4.80). Compared with participants with non-MetS and low genetic risk, those with MetS and high genetic risk had the highest risk of kidney cancer (HR= 1. 74, 95% CI: 1.41-2.14). Conclusions Both pre-MetS and MetS status were positively associated with kidney cancer risk. The risk associated with kidney cancer varied by combinations of MetS components. These findings may offer novel perspectives on the aetiology of kidney cancer and assist in designing primary prevention strategies.
- Published
- 2024
- Full Text
- View/download PDF
123. An epidemiological and clinicopathological study of type 1 vs. type 2 morphological subtypes of papillary renal cell carcinoma– results from a nation-wide study covering 50 years in Iceland
- Author
-
Thorri Geir Runarsson, Andreas Bergmann, Gigja Erlingsdottir, Vigdis Petursdottir, Leon Arnar Heitmann, Aevar Johannesson, Viktor Asbjornsson, Tomas Axelsson, Rafn Hilmarsson, and Tomas Gudbjartsson
- Subjects
Papillary renal cell carcinoma ,Renal cell carcinoma ,Histology ,Subtyping ,Kidney cancer ,Renal cancer ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Abstract Introduction Papillary renal cell carcinoma (pRCC) is the second most common histology of renal cell carcinoma (RCC), accounting for 10–15% of cases. Traditionally, pRCC is divided into type 1 and type 2, although this division is currently debated as a prognostic factor of survival. Our aim was to investigate the epidemiology and survival of the pRCC subtypes in a whole nation cohort of patients during a 50-year period. Materials and methods A Population based retrospective study including consecutive cases of RCC in Iceland from 1971–2020. Comparisons were made between histological classifications of RCC, with emphasis on pRCC subtypes (type 1 vs. 2) for outcome estimation. Changes in RCC incidence were analyzed in 5-year intervals after age standardization. The Kaplan–Meier method and Cox regression were used for outcome analysis. Results A total of 1.725 cases were identified, with 74.4%, 2.1% and 9.2% having clear cell (ccRCC), chromophobe (chRCC), and pRCC, respectively. The age standardized incidence (ASI) of pRCC was 1.97/100.000 for males and 0.5/100.000 for females, and the proportion of pRCC increased from 3.7% to 11.5% between the first and last intervals of the study (p
- Published
- 2024
- Full Text
- View/download PDF
124. Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients
- Author
-
Johannes Uhlig, Annemarie Uhlig, Hari Deshpande, Philipp Ströbel, Lutz Trojan, Joachim Lotz, Michael Hurwitz, Omeed Hafez, Peter Humphrey, Viktor Grünwald, and Hyun S. Kim
- Subjects
Renal cancer ,Renal sarcoma ,Epidemiology ,Survival ,Surgery ,Medicine ,Science - Abstract
Abstract To assess epidemiology, clinical presentation, treatment and overall survival of adult patients with renal sarcomas, the 2004–2016 SEER and NCDB databases were queried for adult patients diagnosed with renal sarcoma, calculating average annual age-adjusted incidence rates (AAIR) and average annual percentage change (AAPC) as well as overall survival (OS). In n = 1279 included renal sarcoma patients, AAIR remained constant over the study period (average 0.53 cases/1million; AAPC = 0.7, p = 0.6). Leiomyosarcoma (AAIR 0.14 cases/1 million) and malignant rhabdoid tumors (0.06 cases/1 million) were most common. Sarcoma histiotypes demonstrated considerable heterogeneity regarding demographic and cancer-related variables. Patients presented with advanced local extent (T3 33.3%; T4 14.2%) or distant metastases (29.1%) and commonly underwent surgical resection (81.6%). Longer OS was independently associated with younger age, female sex, lower comorbidity index, low T stage, negative surgical margins, absence of tumor necrosis or distant metastases and leiomyosarcoma histiotype (multivariable p
- Published
- 2024
- Full Text
- View/download PDF
125. Preparing for the Worst: Management and Predictive Factors of Open Conversion During Minimally Invasive Renal Tumor Surgery (UroCCR-135 Study)
- Author
-
Nicolas Branger, Nicolas Doumerc, Thibaut Waeckel, Pierre Bigot, Louis Surlemont, Sophie Knipper, Géraldine Pignot, François Audenet, Frank Bruyère, Alexis Fontenil, Bastien Parier, Cécile Champy, Morgan Rouprêt, Jean-Jacques Patard, François Henon, Gaëlle Fiard, Julien Guillotreau, Jean-Baptiste Beauval, Constance Michel, Simon Bernardeau, Fayek Taha, Richard Mallet, Frederic Panthier, Laurent Guy, Louis Vignot, Zine-Eddine Khene, and Jean-Christophe Bernhard
- Subjects
Renal cancer ,Open conversion ,Robot-assisted surgery ,Laparoscopic surgery ,Surgical complication ,Intraoperative complication ,Diseases of the genitourinary system. Urology ,RC870-923 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background and objective: Data regarding open conversion (OC) during minimally invasive surgery (MIS) for renal tumors are reported from big databases, without precise description of the reason and management of OC. The objective of this study was to describe the rate, reasons, and perioperative outcomes of OC in a cohort of patients who underwent MIS for renal tumor initially. The secondary objective was to find the factors associated with OC. Methods: Between 2008 and 2022, of the 8566 patients included in the UroCCR project prospective database (NCT03293563), who underwent laparoscopic or robot-assisted minimally invasive partial (MIPN) or radical (MIRN) nephrectomy, 163 experienced OC. Each center was contacted to enlighten the context of OC: “emergency OC” implied an immediate life-threatening situation not reasonably manageable with MIS, otherwise “elective OC”. To evaluate the predictive factors of OC, a 2:1 paired cohort on the UroCCR database was used. Key findings and limitations: The incidence rate of OC was 1.9% for all cases of MIS, 2.9% for MIRN, and 1.4% for MIPN. OC procedures were mostly elective (82.2%). The main reason for OC was a failure to progress due to anatomical difficulties (42.9%). Five patients (3.1%) died within 90 d after surgery. Increased body mass index (BMI; odds ratio [OR]: 1.05, 95% confidence interval [CI]: 1.01–1.09, p = 0.009) and cT stage (OR: 2.22, 95% CI: 1.24–4.25, p = 0.008) were independent predictive factors of OC. Conclusions and clinical implications: In MIS for renal tumors, OC was a rare event (1.9%), caused by various situations, leading to impaired perioperative outcomes. Emergency OC occurred once every 300 procedures. Increased BMI and cT stage were independent predictive factors of OC. Patient summary: The incidence rate of open conversion (OC) in minimally invasive surgery for renal tumors is low. Only 20% of OC procedures occur in case of emergency, and others are caused by various situations. Increased body mass index and cT stage were independent predictive factors of OC.
- Published
- 2024
- Full Text
- View/download PDF
126. Single-cell transcriptional profiling of clear cell renal cell carcinoma reveals a tumor-associated endothelial tip cell phenotype.
- Author
-
Zvirblyte, Justina, Nainys, Juozas, Juzenas, Simonas, Goda, Karolis, Kubiliute, Raimonda, Dasevicius, Darius, Kincius, Marius, Ulys, Albertas, Jarmalaite, Sonata, and Mazutis, Linas
- Subjects
- *
RENAL cell carcinoma , *ENDOTHELIAL cells , *PHENOTYPES , *RENAL cancer , *STROMAL cells - Abstract
Clear cell renal cell carcinoma (ccRCC) is the most prevalent form of renal cancer, accounting for over 75% of cases. The asymptomatic nature of the disease contributes to late-stage diagnoses and poor survival. Highly vascularized and immune infiltrated microenvironment are prominent features of ccRCC, yet the interplay between vasculature and immune cells, disease progression and response to therapy remains poorly understood. Using droplet-based single-cell RNA sequencing we profile 50,236 transcriptomes from paired tumor and healthy adjacent kidney tissues. Our analysis reveals significant heterogeneity and inter-patient variability of the tumor microenvironment. Notably, we discover a previously uncharacterized vasculature subpopulation associated with epithelial-mesenchymal transition. The cell-cell communication analysis reveals multiple modes of immunosuppressive interactions within the tumor microenvironment, including clinically relevant interactions between tumor vasculature and stromal cells with immune cells. The upregulation of the genes involved in these interactions is associated with worse survival in the TCGA KIRC cohort. Our findings demonstrate the role of tumor vasculature and stromal cell populations in shaping the ccRCC microenvironment and uncover a subpopulation of cells within the tumor vasculature that is associated with an angiogenic phenotype. A comprehensive single-cell analysis of clear cell renal cell carcinoma reveals a previously uncharacterized tip-cell like endothelial phenotype and uncovers immunosuppressive clinically relevant targetable interactions in the tumor microenvironment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
127. Acute kidney injury in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody vs. immune checkpoint inhibitors: a retrospective real-world study.
- Author
-
Zhu, Jianfen, Ding, Xiaokai, Zhang, Jianna, Chen, Bo, You, Xiaohan, Chen, Xinxin, and Chen, Tianxin
- Subjects
- *
ENDOTHELIAL growth factors , *IMMUNE checkpoint inhibitors , *ACUTE kidney failure , *RENAL cancer , *CANCER patients , *VASCULAR endothelial growth factor antagonists - Abstract
Background: Anti-vascular endothelial growth factor monoclonal antibody (anti-VEGF) or immune checkpoint inhibitors (ICIs) combined with chemotherapy are commonly administered to cancer patients. Although cancer patients receiving anti-VEGF or ICIs have been reported to experience an increased risk of acute kidney injury (AKI), comparative studies on the AKI incidence have not been evaluated. Methods: Cancer patients receiving anti-VEGF or ICIs were retrospectively selected from the hospital information system of the First Affiliated Hospital of Wenzhou Medical University between Jan, 2020 and Dec, 2022 and were divided into two groups according to the treatment regimen: anti-VEGF group and ICIs group. The baseline characteristics were propensity-score matched. The primary outcome was sustained AKI. A comparison of cumulative incidence of sustained AKI was performed by Kaplan-Meier curves and log-rank test. Risks for outcomes were assessed using Cox proportional regression. Results: A total of 1581 cancer patients receiving anti-VEGF (n = 696) or ICIs (n = 885) were included in the primary analysis. The ICIs group had a higher cumulative incidence of sustained AKI within one year than the anti-VEGF group (26.8% vs. 17.8%, P < 0.001). Among 1392 propensity score matched patients, ICIs therapy (n = 696) was associated with an increased risk of sustained AKI events in the entire population (HR 2.0; 95%CI 1.3 to 2.5; P = 0.001) and especially in those with genitourinary cancer (HR 4.2; 95%CI 1.3 to 13.2; P = 0.015). Baseline serum albumin level (> 35 g/l) was an important risk factor for a lower incidence of sustained AKI in the anti-VEGF group (HR 0.5; 95%CI 0.3 to 0.9; P = 0.027) and the ICIs group (HR 0.3; 95%CI 0.2 to 0.5; P < 0.001). Conclusions: Among cancer patients in this real-world study, treatment with ICIs increased incidence of sustained AKI in one year. Baseline serum albumin level was an important risk factor for sustained AKI. The risk factors for sustained AKI differed between the anti-VEGF group and the ICIs group. Trial Registration: The study has been registered at ClinicalTrials.gov (NCT06119347) on 11/06/2023. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
128. Correlation between hemoglobin and the risk of common malignant tumors: a 1999–2020 retrospective analysis and causal association analysis.
- Author
-
Li, Guo-Sheng, Huang, Tao, Li, Jing-Xiao, Liu, Jun, Gao, Xiang, Yang, Nuo, and Zhou, Hua-Fu
- Subjects
- *
SKIN cancer , *PROSTATE cancer , *HEALTH & Nutrition Examination Survey , *PROSTATE cancer prognosis , *RENAL cancer , *GENOME-wide association studies , *ESOPHAGEAL cancer - Abstract
Background: The role of hemoglobin (HGB) in common malignant tumors remains unclear. Methods: A retrospective analysis was conducted to identify the correlation between HGB levels and risk of 15 malignant tumors using 50,085 samples from the National Health and Nutrition Examination Survey. Mendelian Randomization analyses (MRAs) were performed based on genome-wide association study data to assess the causal relationship between HGB levels and these malignant tumors using more than 700,000 samples. The robustness of the MRA results was confirmed through various analytical methods. Fifty-six in-house samples were used to investigate the correlation between HGB levels and the prognosis in prostate cancer (PRCA) using the Kaplan-Meier curve. Results: High HGB levels were associated with a higher risk for patients with cervix cancer, melanoma, and non-melanoma skin cancer (OR > 1.000, p < 0.05). It served as a protective factor for colon cancer, esophagus cancer, stomach cancer, bone cancer, lung cancer, renal cancer, and PRCA (OR < 1.000, p < 0.05). Furthermore, MRAs suggested that elevated HGB levels were correlated with a reduced risk of PRCA (OR = 0.869, p < 0.05), with no significant association observed between this marker and the remaining 14 malignant tumors. No pleiotropy or heterogeneity was found in the ultimate results for MRAs (p-values > 0.05), suggesting the robustness of the results. The results derived from the in-house data revealed a relationship between higher HGB values and a more favorable prognosis in PRCA (p < 0.05). Conclusion: High circulating HGB levels may play a protective prognostic role for PRCA and serve as a protective factor against the occurrence of PRCA. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
129. Integrated mendelian randomization analyses highlight AFF3 as a novel eQTL-mediated susceptibility gene in renal cancer and its potential mechanisms.
- Author
-
Wang, Qiming, Chen, Shaopeng, Wang, Gang, Zhang, Tielong, and Gao, Yulong
- Subjects
- *
RENAL cancer , *CANCER genes , *LOCUS (Genetics) , *ODDS ratio - Abstract
Backgrounds: A growing number of expression quantitative trait loci (eQTLs) have been found to be linked with tumorigenesis. In this article, we employed integrated Mendelian randomization (MR) analyses to identify novel susceptibility genes in renal cancer (RC) and reveal their potential mechanisms. Methods: Two-sample MR analyses were performed to infer causal relationships between eQTLs, metabolites, and RC risks through the "TwoSampleMR" R package. Sensitivity analyses, such as heterogeneity, pleiotropy, and leave-one-out analysis, were used to assess the stability of our outcomes. Summary-data-based MR (SMR) analyses were used to verify the causal relationships among cis-eQTLs and RC risks via the SMR 1.3.1 software. Results: Our results provided the first evidence for AFF3 eQTL elevating RC risks, suggesting its oncogenic roles (IVW method; odds ratio (OR) = 1.0005; 95% confidence interval (CI) = 1.0001–1.0010; P = 0.0285; heterogeneity = 0.9588; pleiotropy = 0.8397). Further SMR analysis validated the causal relationships among AFF3 cis-eQTLs and RC risks (P < 0.05). Moreover, the TCGA-KIRC, the ICGC-RC, and the GSE159115 datasets verified that the AFF3 gene was more highly expressed in RC tumors than normal control via scRNA-sequencing and bulk RNA-sequencing (P < 0.05). Gene set enrichment analysis (GSEA) analysis identified six potential biological pathways of AFF3 involved in RC. As for the potential mechanism of AFF3 in RC, we concluded in this article that AFF3 eQTL could negatively modulate the levels of the X-11,315 metabolite (IVW method; OR = 0.9127; 95% CI = 0.8530–0.9765; P = 0.0081; heterogeneity = 0.4150; pleiotropy = 0.8852), exhibiting preventive effects against RC risks (IVW method; OR = 0.9987; 95% CI = 0.9975–0.9999; P = 0.0380; heterogeneity = 0.5362; pleiotropy = 0.9808). Conclusions: We concluded that AFF3 could serve as a novel eQTL-mediated susceptibility gene in RC and reveal its potential mechanism of elevating RC risks via negatively regulating the X-11,315 metabolite levels. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
130. Unconventional mechanism of action and resistance to rapalogs in renal cancer.
- Author
-
Juan Yang, Butti, Ramesh, Cohn, Shannon, Toffessi-Tcheuyap, Vanina, Mal, Arijit, Mylinh Nguyen, Stevens, Christina, Christie, Alana, Mishra, Akhilesh, Yuanqing Ma, Jiwoong Kim, Abraham, Robert, Kapur, Payal, Hammer, Robert E., and Brugarolas, James
- Subjects
- *
RENAL cancer , *RENAL cell carcinoma , *TUMOR microenvironment , *ANTINEOPLASTIC agents , *ENGINEERS , *SHALE oils , *IMMUNOCOMPROMISED patients - Abstract
mTORC1 is aberrantly activated in renal cell carcinoma (RCC) and is targeted by rapalogs. As for other targeted therapies, rapalogs clinical utility is limited by the development of resistance. Resistance often results from target mutation, but mTOR mutations are rarely found in RCC. As in humans, prolonged rapalog treatment of RCC tumorgrafts (TGs) led to resistance. Unexpectedly, explants from resistant tumors became sensitive both in culture and in subsequent transplants in mice. Notably, resistance developed despite persistent mTORC1 inhibition in tumor cells. In contrast, mTORC1 became reactivated in the tumor microenvironment (TME). To test the role of the TME, we engineered immunocompromised recipient mice with a resistance mTOR mutation (S2035T). Interestingly, TGs became resistant to rapalogs in mTORS2035T mice. Resistance occurred despite mTORC1 inhibition in tumor cells and could be induced by coculturing tumor cells with mutant fibroblasts. Thus, enforced mTORC1 activation in the TME is sufficient to confer resistance to rapalogs. These studies highlight the importance of mTORC1 inhibition in nontumor cells for rapalog antitumor activity and provide an explanation for the lack of mTOR resistance mutations in RCC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
131. Combined Germline and Mosaic SDHA Mutation Is Associated With a Multicancer Syndrome Including Neuroblastoma, Renal Cancer, and Multifocal GI Tumor.
- Author
-
Cranmer, Lee D., Konnick, Eric Q., Yoshida, Jennifer R., Jacobson, Angela L., Malik, Bilal A., Mogal, Harveshp, Sullivan, Lucas B., Handfrod, Cynthia L., Pritchard, Colin C., and Dubard-Gault, Marianne E.
- Subjects
- *
RENAL cancer , *GERM cells , *NEUROBLASTOMA , *SYNDROMES , *TUMORS , *GENETIC mutation - Abstract
Highlighting here a patient case with neuroblastoma, renal cancer & GIST from germline SDHA. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
132. FPGA implementation of deep learning architecture for kidney cancer detection from histopathological images.
- Author
-
Lal, Shyam, Chanchal, Amit Kumar, Kini, Jyoti, and Upadhyay, Gopal Krishna
- Subjects
DEEP learning ,RENAL cancer ,EARLY detection of cancer ,FIELD programmable gate arrays ,RENAL cell carcinoma ,IMAGE recognition (Computer vision) - Abstract
Kidney cancer is the most common type of cancer, and designing an automated system to accurately classify the cancer grade is of paramount importance for a better prognosis of the disease from histopathological kidney cancer images. Application of deep learning neural networks (DLNNs) for histopathological image classification is thriving and implementation of these networks on edge devices has been gaining the ground correspondingly due to high computational power and low latency requirements. This paper designs an automated system that classifies histopathological kidney cancer images. For experimentation, we have collected Kidney histopathological images of Non-cancerous, cancerous, and their respective grade of Renal Cell Carcinoma (RCC) from Kasturba Medical College (KMC), Mangalore, Karnataka, India. We have implemented and analyzed performances of deep learning architectures on a Field Programmable Gate Array (FPGA) board. Results yield that the Inception-V3 network provides better accuracy for kidney cancer detection as compared to other deep learning models on Kidney histopathological images. Further, the DenseNet-169 network provides better accuracy for kidney cancer grading as compared to other existing deep learning architecture on the FPGA board. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
133. A 23-year bibliometric analysis of the development of global research on hereditary renal carcinoma.
- Author
-
Xiaopeng Lan, Mei Feng, Ji Lv, Luchen Zhang, Pengcheng Hu, Yizhen Wang, Yanhui Zhang, Shen Wang, Chunzhao Liu, and Chunlei Liu
- Subjects
BIBLIOMETRICS ,RENAL cancer ,RENAL cell carcinoma ,MEDICAL research ,CARCINOMA - Abstract
Objectives: Medical research continues to be extensively devoted to investigating the pathogenesis and treatment approaches of hereditary renal cancer. By aspect including researchers, institutions, countries, journals, and keywords, we conduct a bibliometric analysis of the literature pertaining to hereditary renal cancer over the last 23 years. Methods: From the Web of Science Core Collection, we conducted a search for publications published between January 1, 2000 and November 28, 2023. Reviews and original articles were included. Results: A cumulative count of 2,194 publications met the specified criteria for inclusion. The studies of the included articles involved a collective of 2,402 institutions representing 80 countries. Notably, the United States exhibited the highest number of published documents, constituting approximately 45.49% of the total. The preeminent institution in this discipline is the National Cancer Institute (NCI), which maintains a publication volume of 8.98%. In addition to being the most prolific author (125 publications), Linehan WM's works received the highest number of citations (11,985). In a comprehensive count, 803 journals have published related articles. In the top 10 most recent occurrences were the terms "hereditary leiomyomatosis" and "fumarate hydratase." Conclusion: This is the first bibliometric analysis of the literature on hereditary renal cancer. This article offers a thorough examination of the present status of investigations concerning hereditary renal cancer during the previous 23 years. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
134. Role of SYT11 in human pan-cancer using comprehensive approaches.
- Author
-
Noh, Kyunghee, Choi, Hyunji, Jo, Eun-Hye, Yoo, Wonbeak, and Park, Kyung Chan
- Subjects
GENE expression ,RENAL cancer ,PROTEIN-protein interactions ,CANCER prognosis ,CELL physiology - Abstract
Background: Synaptotagmin 11 (SYT11) plays a pivotal role in neuronal vesicular trafficking and exocytosis. However, no independent prognostic studies have focused on various cancers. In this study, we aimed to summarize the clinical significance and molecular landscape of SYT11 in various tumor types. Methods: Using several available public databases, we investigated abnormal SYT11 expression in different tumor types and its potential clinical association with prognosis, methylation profiling, immune infiltration, gene enrichment analysis, and protein–protein interaction analysis, and identified common pathways. Results: TCGA and Genotype-Tissue Expression (GTEx) showed that SYT11 was widely expressed across tumor and corresponding normal tissues. Survival analysis showed that SYT11 expression correlated with the prognosis of seven cancer types. Additionally, SYT11 mRNA expression was not affected by promoter methylation, but regulated by certain miRNAs and associated with cancer patient prognosis. In vitro experiments further verified a negative correlation between the expression of SYT11 and miR-19a-3p in human colorectal, lung, and renal cancer cell lines. Moreover, aberrant SYT11 expression was significantly associated with immune infiltration. Pathway enrichment analysis revealed that the biological and molecular processes of SYT11 were related to clathrin-mediated endocytosis, Rho GTPase signaling, and cell motility-related functions. Conclusions: Our results provide a clear understanding of the role of SYT11 in various cancer types and suggest that SYT11 may be of prognostic and clinical significance. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
135. Kidney cancer in the Middle East and North Africa region: a 30-year analysis (1990–2019).
- Author
-
Safiri, Saeid, Hassanzadeh, Kamaleddin, Ghaffari Jolfayi, Amir, Mousavi, Seyed Ehsan, Motlagh Asghari, Kimia, Nejadghaderi, Seyed Aria, Naghdi-Sedeh, Nima, Noori, Maryam, Sullman, Mark J. M., Collins, Gary S., and Kolahi, Ali-Asghar
- Subjects
- *
RENAL cancer , *KIDNEYS , *GLOBAL burden of disease - Abstract
Kidney cancer, a type of urogenital cancer, imposes a high burden on patients. Despite this, no recent research has evaluated the burden of this type of cancer in the Middle East and North Africa (MENA) region. This study explored the burden of kidney cancer from 1990 to 2019 according to age, sex and socio-demographic index (SDI). The Global Burden of Disease (GBD) 2019 data was utilized to estimate the incidence, death, and disability-adjusted life-years (DALYs) caused by kidney cancer. These estimates were reported as counts and as age-standardised rates with 95% uncertainty intervals (UIs). The estimated age-standardised incidence, mortality, and DALY rates of kidney cancer in 2019 were 3.2 (2.8–3.6), 1.4 (1.2–1.6), and 37.2 (32.0–42.6) per 100,000, respectively. Over the period from 1990 to 2019, these rates have increased by 98.0%, 48.9%, and 37.7%, respectively. In 2019, the United Arab Emirates, Qatar, and Lebanon had the largest age-standardised incidence, mortality, and DALY rates. The smallest age-standardised incidence rates were seen in Yemen, Afghanistan, and the Syrian Arab Republic. Additionally, the smallest age-standardised mortality and DALY rates were observed in the Syrian Arab Republic, Yemen, and Morocco. The highest incidence rates were found among individuals aged 75–79 in both males and females. In 2019, the MENA/Global DALY ratio exceeded one for females aged 5–19 age and males aged 5–14, compared to 1990age groups in males. The burden of kidney cancer consistently rose with increasing SDI levels from 1990 to 2019. The increasing burden of kidney cancer highlights the urgent need for interventions aimed at improving early diagnosis and treatment in the region. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
136. Metabolomics Reveals Tyrosine Kinase Inhibitor Resistance-Associated Metabolic Events in Human Metastatic Renal Cancer Cells.
- Author
-
Amaro, Filipa, Carvalho, Márcia, Bastos, Maria de Lourdes, Guedes de Pinho, Paula, and Pinto, Joana
- Subjects
- *
PROTEIN-tyrosine kinase inhibitors , *RENAL cancer , *ENZYME inhibitors , *METABOLIC reprogramming , *METASTASIS , *METABOLOMICS , *PROTEIN-tyrosine kinases , *NICOTINAMIDE - Abstract
The development of resistance to tyrosine kinase inhibitors (TKIs) is a major cause of treatment failure in metastatic renal cell carcinoma (mRCC). A deeper understanding of the metabolic mechanisms associated with TKI resistance is critical for refining therapeutic strategies. In this study, we established resistance to sunitinib and pazopanib by exposing a parental Caki-1 cell line to increasing concentrations of sunitinib and pazopanib. The intracellular and extracellular metabolome of sunitinib- and pazopanib-resistant mRCC cells were investigated using a nuclear magnetic resonance (NMR)-based metabolomics approach. Data analysis included multivariate and univariate methods, as well as pathway and network analyses. Distinct metabolic signatures in sunitinib- and pazopanib-resistant RCC cells were found for the first time in this study. A common metabolic reprogramming pattern was observed in amino acid, glycerophospholipid, and nicotinate and nicotinamide metabolism. Sunitinib-resistant cells exhibited marked alterations in metabolites involved in antioxidant defence mechanisms, while pazopanib-resistant cells showed alterations in metabolites associated with energy pathways. Sunitinib-resistant RCC cells demonstrated an increased ability to proliferate, whereas pazopanib-resistant cells appeared to restructure their energy metabolism and undergo alterations in pathways associated with cell death. These findings provide potential targets for novel therapeutic strategies to overcome TKI resistance in mRCC through metabolic regulation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
137. Whole-Exome Sequencing Revealed a Pathogenic Germline Variant in the Fumarate Hydratase Gene, Leading to the Diagnosis of Hereditary Leiomyomatosis and Renal Cell Cancer.
- Author
-
Nagashima, Akari, Morimura, Sohshi, Hamada, Toshihisa, Shiomi, Takayuki, Mori, Ichiro, Sato, Naoko, Nomoto, Junko, Tanaka, Masaki, Tsuji, Shoji, and Sugaya, Makoto
- Subjects
- *
RENAL cancer , *HEREDITARY cancer syndromes , *CANCER cells , *GERM cells , *DIAGNOSIS , *GENETIC disorders - Abstract
The diagnosis of hereditary skin tumors is difficult for "old" diagnostic tools such as immunohistochemistry. Whole-exome sequencing analysis as a "new" diagnostic tool enables us to make a final diagnosis in spite of unknown hereditary diseases in the past. Hereditary leiomyomatosis and renal cell cancer are autosomal dominant hereditary cancer syndromes characterized by uterine myomas, cutaneous leiomyomas, and aggressive renal cell cancer. The syndrome is associated with pathogenic germline variants in the fumarate hydratase gene. Herein, we demonstrate a pathogenic germline variant of the fumarate hydratase gene in a 60-year-old woman with multiple cutaneous leiomyomas, leading to the diagnosis of hereditary leiomyomatosis and renal cell cancer. Whole-exome sequencing analysis using genomic DNA extracted from peripheral blood leukocytes revealed one germline variant in the FH gene on chromosome 1 (c.290G>A, p.Gly97Asp). She received total hysterectomy due to uterine myoma, which strongly supported the diagnosis. No tumor was detected in her kidney by computed tomography and ultrasound examination. Genetic examination for the mutation of the fumarate hydratase gene is important in order to reach the correct diagnosis and to detect renal cancer at its early stage. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
138. The establishment of kidney cancer organoid line in drug testing.
- Author
-
Tse, Ryan Tsz‐Hei, Wong, Christine Yim‐Ping, Ding, Xiaofan, Cheng, Carol Ka‐Lo, Chow, Chit, Chan, Ronald Cheong‐Kin, Ng, Joshua Hoi‐Yan, Tang, Victor Wai‐Lun, Chiu, Peter Ka‐Fung, Teoh, Jeremy Yuen‐Chun, Wong, Nathalie, To, Ka‐Fai, and Ng, Chi‐Fai
- Subjects
- *
RENAL cancer , *DRUG use testing , *MICROPHYSIOLOGICAL systems , *RENAL cell carcinoma , *XENOGRAFTS , *KIDNEY tumors - Abstract
Introduction: Kidney cancer is a common urological malignancy worldwide with an increasing incidence in recent years. Among all subtypes, renal cell carcinoma (RCC) represents the most predominant malignancy in kidney. Clinicians faced a major challenge to select the most effective and suitable treatment regime for patients from a wide range of modalities, despite improved understanding and diagnosis of RCC. Objective: Recently, organoid culture gained more interest as the 3D model is shown to be highly patient specific which is hypothetically beneficial to the investigation of precision medicine. Nonetheless, the development and application of organotypic culture in RCC is still immature, therefore, the primary objective of this study was to establish an organoid model for RCC. Materials and Methods: Patients diagnosed with renal tumor and underwent surgical intervention were recruited. RCC specimen was collected and derived into organoids. Derived organoids were validated by histological examminations, sequencing and xenograft. Drug response of organoids were compared with resistance cell line and patients' clinical outcomes. Results: Our results demonstrated that organoids could be successfully derived from renal tumor and they exhibited high concordance in terms of immunoexpressional patterns. Sequencing results also depicted concordant mutations of driver genes in both organoids and parental tumor tissues. Critical and novel growth factors were discovered during the establishment of organoid model. Besides, organoids derived from renal tumor exhibited tumorigenic properties in vivo. In addition, organoids recapitulated patient's in vivo drug resistance and served as a platform to predict responsiveness of other therapeutic agents. Conclusion: Our RCC organoid model recaptiluated histological and genetic features observed in primary tumors. It also served as a potential platform in drug screening for RCC patients, though future studies are necessary before translating the outcomes into clinical practices. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
139. The role of metabolic reprogramming in kidney cancer.
- Author
-
Ziyi Chen and Xiaohong Zhang
- Subjects
METABOLIC reprogramming ,RENAL cancer ,AMINO acid metabolism - Abstract
Metabolic reprogramming is a cellular process in which cells modify their metabolic patterns to meet energy requirements, promote proliferation, and enhance resistance to external stressors. This process also introduces new functionalities to the cells. The ‘Warburg effect’ is a well-studied example of metabolic reprogramming observed during tumorigenesis. Recent studies have shown that kidney cells undergo various forms of metabolic reprogramming following injury. Moreover, metabolic reprogramming plays a crucial role in the progression, prognosis, and treatment of kidney cancer. This review offers a comprehensive examination of renal cancer, metabolic reprogramming, and its implications in kidney cancer. It also discusses recent advancements in the diagnosis and treatment of renal cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
140. Ambient air pollution and urological cancer risk: A systematic review and meta-analysis of epidemiological evidence.
- Author
-
Li, Jinhui, Deng, Zhengyi, Soerensen, Simon John Christoph, Kachuri, Linda, Cardenas, Andres, Graff, Rebecca E., Leppert, John T., Langston, Marvin E., and Chung, Benjamin I.
- Subjects
AIR pollution ,DISEASE risk factors ,AIR quality ,RENAL cancer ,PROSTATE cancer - Abstract
Exposure to ambient air pollution has significant adverse health effects; however, whether air pollution is associated with urological cancer is largely unknown. We conduct a systematic review and meta-analysis with epidemiological studies, showing that a 5 μg/m
3 increase in PM2.5 exposure is associated with a 6%, 7%, and 9%, increased risk of overall urological, bladder, and kidney cancer, respectively; and a 10 μg/m3 increase in NO2 is linked to a 3%, 4%, and 4% higher risk of overall urological, bladder, and prostate cancer, respectively. Were these associations to reflect causal relationships, lowering PM2.5 levels to 5.8 μg/m3 could reduce the age-standardized rate of urological cancer by 1.5 ~ 27/100,000 across the 15 countries with the highest PM2.5 level from the top 30 countries with the highest urological cancer burden. Implementing global health policies that can improve air quality could potentially reduce the risk of urologic cancer and alleviate its burden. Whether air pollufion is associated with urological cancer is largely unknown. In this study, the authors reveal correlafions between air pollufion and urological cancer risk: an increase of 5 μg/m3 in PM2.5 and 10 μg/m3 in NO2 would raise risks by 6-9% and 3-4%, respecfively; while lowering PM2.5 to 5.8 μg/m3 may reduce urological cancer burden. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
141. Belzutifan: a novel therapeutic for the management of von Hippel–Lindau disease and beyond.
- Author
-
Curry, Lauren and Soleimani, Maryam
- Abstract
The identification of the VHL gene and its role in regulating the hypoxia-inducible factor signaling pathway has helped to revolutionize the treatment of renal cell carcinoma (RCC). Belzutifan is a novel small-molecule inhibitor of hypoxia-inducible factor 2α which has demonstrated efficacy in treating von Hippel–Lindau (VHL) disease, earning regulatory approvals for this indication. There is also early evidence for efficacy in sporadic RCC. Belzutifan has a favorable safety profile. Several clinical trials are currently ongoing, which should help in identifying this promising drug's role in RCC and beyond. This review summarizes the history, pharmacology and clinical evidence for belzutifan use to date, and also explores unanswered questions as they relate to this novel therapeutic agent. The novel drug belzutifan was developed after years of research in identifying the VHL gene and how genetic abnormalities in VHL may result in tumor growth. Belzutifan has been approved for use in patients with VHL disease – a rare familial disorder first described in the 19th century that presents with a variety of cancerous and noncancerous tumors, including kidney cancer. Growing evidence supports belzutifan's use in non-familial kidney cancer as well. This is important because most patients eventually develop resistance to the currently available cancer treatments, highlighting the need for drugs with a different mechanism of action. Belzutifan works by blocking a protein called HIF-2a, which causes tumor growth in patients with VHL disease. Belzutifan is well tolerated, with the most common side effects being low energy, hemoglobin and blood oxygen. This review summarizes the history, mechanism of action and research evidence to date supporting the use of belzutifan in VHL disease and cancer treatment. We also discuss future directions, including remaining clinical questions and areas of ongoing research. Executive summary Introduction Although the last decade has ushered in a new era of systemic therapy options for the management of metastatic renal cell carcinoma (RCC), including molecular targeted therapies and immune checkpoint inhibitors, most patients will eventually develop disease progression. This emphasizes the need for therapeutics with alternative mechanisms of action in the management of metastatic RCC. The VHL gene & its role in the cellular oxygen sensing pathway The VHL gene was identified in 1993, nearly a century after the first historical descriptions of von Hippel–Lindau (VHL) disease. VHL disease is caused by a germline variant in VHL, with an additional somatic inactivation/deletion of VHL in tumor cells. Variants in VHL may manifest in the absence of functional VHL protein, creating a cellular pseudohypoxic state whereby hypoxia-inducible factor (HIF) transcription factors are not degraded as they normally are in the presence of oxygen, ultimately leading to proangiogenic and tumorigenic gene expression. Belzutifan clinical pharmacology Belzutifan (MK-6482) is a first-in-class, second-generation HIF-2α inhibitor that selectively disrupts the heterodimerization of the HIF transcription complex, preventing downstream target gene transcription and resultant oncogenesis. Evidence to date suggests that belzutifan has a well-tolerated toxicity profile. The most commonly experienced side effects include fatigue, anemia and hypoxia. Clinical efficacy of belzutifan LITESPARK-001 was the first-in-human, phase I study of belzutifan that investigated its pharmacodynamics, pharmacokinetics and toxicity in 95 patients with locally advanced or metastatic solid tumors. In this study, belzutifan was well tolerated without dose-limiting toxicities, establishing 120 mg once daily as the recommended phase II dose. Belzutifan for VHL disease was first evaluated in the nonrandomized, phase II LITESPARK-004 study, in which 61 patients with VHL-associated, localized RCC were treated with belzutifan 120 mg orally daily. The demonstrated efficacy for RCC and non-RCC lesions led to the US FDA's approval of belzutifan in 2021 for the treatment of adult patients with VHL disease, with Health Canada and other regulatory bodies following suit. The interim analysis of the phase III study LITESPARK-005 was presented at the European Society for Medical Oncology Congress in 2023, showing superior objective response rate and progression-free survival for belzutifan compared with everolimus in previously treated patients with advanced RCC. Discussion To date, belzutifan has not been approved in any jurisdiction for treatment beyond VHL disease, for which the evidence is most robust. Growing evidence suggests belzutifan's efficacy in sporadic RCC; however, its place in the treatment algorithm has not yet been clearly established due the paucity of phase III trial evidence. There are numerous phase III trials evaluating the safety and efficacy of belzutifan in combination with other treatments in the second- and first-line and adjuvant settings for RCC. If belzutifan finds its way into the armamentarium of systemic therapy for metastatic RCC, this agent could be practice-changing beyond the VHL population. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
142. Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastrophe.
- Author
-
Rachamala, Hari K., Madamsetty, Vijay S., Angom, Ramcharan S., Nakka, Naga M., Dutta, Shamit Kumar, Wang, Enfeng, Mukhopadhyay, Debabrata, and Pal, Krishnendu
- Subjects
- *
EVEROLIMUS , *RENAL cell carcinoma , *DNA repair , *RADIOTHERAPY , *DNA damage , *RADIOTHERAPY safety , *STEREOTACTIC radiotherapy , *DOSE-response relationship (Radiation) - Abstract
Background: Renal cell carcinoma (RCC) was historically considered to be less responsive to radiation therapy (RT) compared to other cancer indications. However, advancements in precision high-dose radiation delivery through single-fraction and multi-fraction stereotactic ablative radiotherapy (SABR) have led to better outcomes and reduced treatment-related toxicities, sparking renewed interest in using RT to treat RCC. Moreover, numerous studies have revealed that certain therapeutic agents including chemotherapies can increase the sensitivity of tumors to RT, leading to a growing interest in combining these treatments. Here, we developed a rational combination of two radiosensitizers in a tumor-targeted liposomal formulation for augmenting RT in RCC. The objective of this study is to assess the efficacy of a tumor-targeted liposomal formulation combining the mTOR inhibitor everolimus (E) with the survivin inhibitor YM155 (Y) in enhancing the sensitivity of RCC tumors to radiation. Experimental design: We slightly modified our previously published tumor-targeted liposomal formulation to develop a rational combination of E and Y in a single liposomal formulation (EY-L) and assessed its efficacy in RCC cell lines in vitro and in RCC tumors in vivo. We further investigated how well EY-L sensitizes RCC cell lines and tumors toward radiation and explored the underlying mechanism of radiosensitization. Results: EY-L outperformed the corresponding single drug-loaded formulations E-L and Y-L in terms of containing primary tumor growth and improving survival in an immunocompetent syngeneic mouse model of RCC. EY-L also exhibited significantly higher sensitization of RCC cells towards radiation in vitro than E-L and Y-L. Additionally, EY-L sensitized RCC tumors towards radiation therapy in xenograft and murine RCC models. EY-L mediated induction of mitotic catastrophe via downregulation of multiple cell cycle checkpoints and DNA damage repair pathways could be responsible for the augmentation of radiation therapy. Conclusion: Taken together, our study demonstrated the efficacy of a strategic combination therapy in sensitizing RCC to radiation therapy via inhibition of DNA damage repair and a substantial increase in mitotic catastrophe. This combination therapy may find its use in the augmentation of radiation therapy during the treatment of RCC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
143. Kidney Cancer and Potential Use of Urinary Extracellular Vesicles.
- Author
-
Linh Nguy-Hoang Le, Munir, Javaria, Eun-Bit Kim, and Seongho Ryu
- Subjects
- *
RENAL cancer , *EXTRACELLULAR vesicles , *RENAL cell carcinoma , *TUMOR markers , *SURVIVAL rate , *KIDNEY diseases - Abstract
Kidney cancer is the 14th most common cancer globally. The 5-year relative survival rate of kidney cancer at a localized stage is 92.9% and it declines to 17.4% in metastatic stage. Currently, the most accurate method of its diagnosis is tissue biopsy. However, the invasive and costly nature of biopsies makes it undesirable in many patients. Therefore, novel biomarkers for diagnosis and prognosis should be explored. Urinary extracellular vesicles (uEVs) are small vesicles (50-200 nm) in urine carrying nucleic acids, proteins and lipids as their cargos. These uEVs' cargos can provide non-invasive alternative to monitor kidney health. In this review, we have summarized recent studies investigating potential use of uEVs' cargos as biomarkers in kidney cancer for diagnosis, prognosis and therapeutic intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
144. Immunotherapy and stereotactic body radiotherapy for older patients with non-metastatic renal cancer unfit for surgery or decline nephrectomy: practical proposal by the International Geriatric Radiotherapy Group.
- Author
-
Nguyen, Nam P., Chirila, Monica-Emilia, Page, Brandi R., Vinh-Hung, Vincent, Gorobets, Olena, Mohammadianpanah, Mohammad, Giap, Huan, Arenas, Meritxell, Bonet, Marta, Lara, Pedro Carlos, Kim, Lyndon, Dutheil, Fabien, Lehrman, David, Montes, Luis Zegarra, Tlili, Ghassen, Dahbi, Zineb, Loganadane, Gokoulakrichenane, Blanco, Sergio Calleja, Bose, Satya, and Natoli, Elena
- Subjects
RENAL cancer ,OLDER patients ,STEREOTACTIC radiotherapy ,RADIOTHERAPY ,ONCOLOGIC surgery ,IMMUNOTHERAPY ,NEPHRECTOMY - Abstract
The standard of care for non-metastatic renal cancer is surgical resection followed by adjuvant therapy for those at high risk for recurrences. However, for older patients, surgery may not be an option due to the high risk of complications which may result in death. In the past renal cancer was considered to be radio-resistant, and required a higher dose of radiation leading to excessive complications secondary to damage of the normal organs surrounding the cancer. Advances in radiotherapy technique such as stereotactic body radiotherapy (SBRT) has led to the delivery of a tumoricidal dose of radiation with minimal damage to the normal tissue. Excellent local control and survival have been reported for selective patients with small tumors following SBRT. However, for patients with poor prognostic factors such as large tumor size and aggressive histology, there was a higher rate of loco-regional recurrences and distant metastases. Those tumors frequently carry program death ligand 1 (PDL1) which makes them an ideal target for immunotherapy with check point inhibitors (CPI). Given the synergy between radiotherapy and immunotherapy, we propose an algorithm combining CPI and SBRT for older patients with nonmetastatic renal cancer who are not candidates for surgical resection or decline nephrectomy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
145. Blood cell indices and inflammation-related markers with kidney cancer risk: a large-population prospective analysis in UK Biobank.
- Author
-
Qingliu He, Chengcheng Wei, Li Cao, Pu Zhang, Wei Zhuang, and Fangzhen Cai
- Subjects
RENAL cancer ,BLOOD cells ,DISEASE risk factors ,TUMOR markers ,ERYTHROCYTES - Abstract
Background: Kidney cancer is a prevalent malignancy with an increasing incidence worldwide. Blood cell indices and inflammation-related markers have shown huge potential as biomarkers for predicting cancer incidences, but that is not clear in kidney cancer. Our study aims to investigate the correlations of blood cell indices and inflammation-related markers with kidney cancer risk. Methods: We performed a population-based cohort prospective analysis using data from the UK Biobank. A total of 466,994 participants, free of kidney cancer at baseline, were included in the analysis. The hazard ratios (HRs) and 95% confidence intervals (CIs) for kidney cancer risk were calculated using Cox proportional hazards regression models. Restricted cubic spline models were used to investigate nonlinear longitudinal associations. Stratified analyses were used to identify high-risk populations. The results were validated through sensitivity analyses. Results: During a mean follow-up of 12.4 years, 1,710 of 466,994 participants developed kidney cancer. The Cox regression models showed that 13 blood cell indices and four inflammation-related markers were associated with kidney cancer incidence. The restricted cubic spline models showed non-linear relationships with kidney cancer. Finally, combined with stratified and sensitivity analyses, we found that the mean corpuscular hemoglobin concentration (MCHC), red blood cell distribution width (RDW), platelet distribution width (PDW), systemic immune-inflammation index (SII), and product of platelet count and neutrophil count (PPN) were related to enhanced kidney cancer risk with stable results. Conclusion: Our findings identified that three blood cell indices (MCHC, RDW, and PDW) and two inflammation-related markers (SII and PPN) were independent risk factors for the incidence of kidney cancer. These indexes may serve as potential predictors for kidney cancer and aid in the development of targeted screening strategies for at-risk individuals. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
146. Fumarate hydratase as a metabolic regulator of immunity.
- Author
-
Peace, Christian G., O'Carroll, Shane M., and O'Neill, Luke A.J.
- Subjects
- *
KREBS cycle , *SYSTEMIC lupus erythematosus , *THERAPEUTICS , *RENAL cancer , *CELL physiology , *TYPE I interferons , *NUCLEIC acids , *PLANT mitochondria - Abstract
Metabolism is a key regulator of immune cell function. Tricarboxylic acid cycle rewiring and metabolites have immunoregulatory roles. Fumarate hydratase (FH) and fumarate are now known to regulate cytokine production. Recent findings suggest FH loss leads to mitochondrial nucleic acid release, leading to type I interferon production. Tricarboxylic acid (TCA) cycle metabolites have been implicated in modulating signalling pathways in immune cells. Notable examples include succinate and itaconate, which have pro- and anti-inflammatory roles, respectively. Recently, fumarate has emerged as having specific roles in macrophage activation, regulating the production of such cytokines as interleukin (IL)-10 and type I interferons (IFNs). Fumarate hydratase (FH) has been identified as a control point. Notably, FH loss in different models and cell types has been found to lead to DNA and RNA release from mitochondria which are sensed by cytosolic nucleic acid sensors including retinoic acid-inducible gene (RIG)-I, melanoma differentiation-associated protein (MDA)5, and cyclic GMP-AMP synthase (cGAS) to upregulate IFN-β production. These findings may have relevance in the pathogenesis and treatment of diseases associated with decreased FH levels such as systemic lupus erythematosus (SLE) or FH-deficient kidney cancer. Tricarboxylic acid (TCA) cycle metabolites have been implicated in modulating signalling pathways in immune cells. Notable examples include succinate and itaconate, which have pro- and anti-inflammatory roles respectively. Recently, fumarate has emerged as having specific roles in macrophage activation, regulating the production of such cytokines as interleukin (IL)-10 and type I interferons (IFNs). Fumarate hydratase (FH) has been identified as a control point. Notably, FH loss in different models and cell types has been found to lead to DNA and RNA release from mitochondria which are sensed by cytosolic nucleic acid sensors including retinoic acid-inducible gene (RIG)-I, melanoma differentiation-associated protein (MDA)5, and cyclic GMP-AMP synthase (cGAS) to upregulate IFN-β production. These findings may have relevance in the pathogenesis and treatment of diseases associated with decreased FH levels such as systemic lupus erythematosus or FH-deficient kidney cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
147. Nurse‐led renal cell carcinoma clinic: a single center review.
- Author
-
Thia, I., Tan, A., Botha, E., Picardo, A., Brown, M., Thyer, I., Abdul‐Hamid, A., Teichmann, D., Hayne, D., and McCombie, S.P.
- Subjects
- *
NEPHRECTOMY , *RENAL cell carcinoma , *COMPUTED tomography , *RENAL cancer , *ONCOLOGY nursing - Abstract
Background: In 2015 our centre introduced a nurse‐led renal cell cancer follow‐up protocol and clinic for patients who have undergone partial or radical nephrectomy for organ‐confined kidney tumours. The main aims of this clinic were to improve healthcare efficiency and standardize follow‐up processes. Objectives: The primary objective was to assess the effectiveness of a nurse‐led renal cell cancer follow up clinic in regard to surveillance protocol compliance and the timely identification and appropriate management of recurrences. A secondary objective was to evaluate this locally developed follow up protocol against the current European Association of Urology (EAU) guidelines surveillance protocol. Patient and Methods: All patients who underwent a partial or radical nephrectomy between 2015 and 2021 at a single Western Australia institution for a primary renal malignancy were included. Data was collected from local clinical information systems and protocol adherence, recurrence characteristics and management were assessed. The current EAU guidelines were applied to the cohort to assess differences in risk‐stratification and theoretical outcomes between the protocols. Results: After a mean follow up period of 31.2 months (range 0–77 months), 75.5% (185/245) of patients had all follow up imaging and reviews within 1 month of the timeframe scheduled on the protocol. 17.1% (42/245) had a delay in their follow up of more than a month at some stage, 5.7% (14/245) did not attend for follow up but had documented attempts to facilitate their compliance, and 0.4% (1/245) were lost to follow up with no evidence of attempted contact. 15.5% (38/245) of patients had recurrence of malignancy detected during follow up and these were all discussed in a multi‐disciplinary team (MDT) meeting. The recurrence rate was 2.5% (3/119) for low risk, 17.7% (14/79) for intermediate risk, and 44.7% (21/47) for high risk patients when they were re‐stratified according to EAU risk categories. No recurrences were detected through ultrasound (USS) or chest x‐ray (CXR) in this cohort and our protocol tended to place patients in higher risk‐stratification groups as compared to current EAU guidelines. Conclusion: Nurse‐led renal cell cancer follow up is a safe, reliable and effective clinical framework that has significant benefits in regard to resource utilization. USS and CXR are ineffective in detecting recurrence and Computerized tomography (CT) should be considered the imaging modality of choice for this purpose. The EAU surveillance protocol appears superior to our protocol, and we have therefore transitioned to the EAU guideline protocol going forward. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
148. Immunotherapy Applications for Thymine Dimers and WT1 Antigen in Renal Cancers: A Comparative Statistical Analysis.
- Author
-
Latcu, Silviu Constantin, Bardan, Razvan, Cumpanas, Alin Adrian, Barbos, Vlad, Baderca, Flavia, Gaje, Pusa Nela, Ceausu, Raluca Amalia, Comsa, Serban, Dumitru, Cristina-Stefania, Dumache, Raluca, Cut, Talida Georgiana, Lazureanu, Voichita Elena, and Petrica, Ligia
- Subjects
- *
RENAL cancer , *MOLECULAR biology , *THYMINE , *NEPHROBLASTOMA , *RENAL cell carcinoma , *RENAL tubular transport disorders , *PHYLLODES tumors - Abstract
Renal cell carcinoma (RCC) remains incurable in advanced stages. Biomarkers have proven to be quite useful in cancer therapeutics. Herein, we provide a comparative/integrative statistical analysis of seminal immunohistochemistry (IHC) findings for Wilms' Tumor 1 antigen (WT1) and thymine dimers (TDs), emerging as atypical, yet promising, potential biomarkers for RCCs. We assessed WT1/TD reactivity in adult RCC tumor cells, tumor microenvironment (TME), and tumor-adjacent healthy renal tissue (HRT). WT1 positivity was scarce and strictly nuclear in tumor cells, whereas TD-reactive tumor tissues were prevalent. We report statistically significant positive correlations between the density of reactive RCC cellularity and the intensity of nuclear staining for both biomarkers (WT1 − rho = 0.341, p-value = 0.036; TDs − rho = 0.379, p-value = 0.002). RCC stromal TME TD-positivity was much more frequent than WT1 reactivity, apparently proportional to that of the proper RCC cellularity and facilitated by extensive RCC inflammatory infiltration. TDs exhibited nuclear reactivity for most TME cell lines, while RCC TME WT1 expression was rare and inconsistent. In HRTs, TDs were entirely restricted to renal tubular cells, the likely cellular progenitor of most conventional RCC subtypes. In lieu of proper validation, these early findings have significant implications regarding the origins/biology of RCCs and may inform RCC therapeutics, both accounting for the high frequency of immunotherapy-permissive frameshift indels in RCCs, but also hinting at novel predictive clinical tools for WT1-targeted immunotherapy. Overall, the current study represents a meek yet hopefully significant step towards understanding the molecular biology and potential therapeutic targets of RCCs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
149. Long-Term Oncologic Outcomes of Off-Clamp Robotic Partial Nephrectomy for Cystic Renal Tumors: A Propensity Score Matched-Pair Comparison of Cystic versus Pure Clear Cell Carcinoma.
- Author
-
Ferriero, Mariaconsiglia, Ragusa, Alberto, Mastroianni, Riccardo, Tuderti, Gabriele, Costantini, Manuela, Anceschi, Umberto, Misuraca, Leonardo, Brassetti, Aldo, Guaglianone, Salvatore, Bove, Alfredo Maria, Leonardo, Costantino, Gallucci, Michele, Papalia, Rocco, and Simone, Giuseppe
- Subjects
- *
RENAL cell carcinoma , *KIDNEY tumors , *ADENOID cystic carcinoma , *NEPHRECTOMY , *RENAL cancer , *REGRESSION analysis - Abstract
Few data are available on survival outcomes of partial nephrectomy performed for cystic renal tumors. We present the first long-term oncological outcomes of cystic (cystRCC) versus pure clear cell renal cell carcinoma (ccRCC) in a propensity score-matched (PSM) analysis. Our "renal cancer" prospectively maintained database was queried for "cystRCC" or "ccRCC" and "off-clamp robotic partial nephrectomy" (off-C RPN). The two groups were compared for age, gender, tumor size, pT stage, and Fuhrman grade. A 1:3 PSM analysis was applied to reduce covariate imbalance to <10% and two homogeneous populations were generated. Student t- and Chi-square tests were used for continuous and categorical variables, respectively. Ten-year oncological outcomes were compared between the two cohorts using log-rank test. Univariable Cox regression analysis was used to identify predictors of disease progression after RPN. Out of 859 off-C RPNs included, 85 cases were cystRCC and 774 were ccRCC at histologic evaluation. After applying the PSM analysis, two cohorts were selected, including 64 cystRCC and 170 ccRCC. Comparable 10-year cancer-specific survival probability (95.3% versus 100%, p = 0.146) was found between the two cohorts. Conversely, 10-year disease-free survival probability (DFS) was less favorable for pure ccRCC than cystRCC (66.69% versus 90.1%, p = 0.035). At univariable regression analysis, ccRCC histology was the only independent predictor of DFS probability (HR 2.96 95% CI 1.03–8.47, p = 0.044). At the 10-year evaluation, cystRCC showed favorable oncological outcomes after off-C RPN. Pure clear cell variant histology displayed a higher rate of disease recurrence than cystic lesions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
150. GDF15, an Emerging Player in Renal Physiology and Pathophysiology.
- Author
-
Lasaad, Samia and Crambert, Gilles
- Subjects
- *
KIDNEY physiology , *PATHOLOGICAL physiology , *RENAL cancer , *DIABETIC nephropathies , *CHRONIC kidney failure - Abstract
These last years, the growth factor GDF15 has emerged as a key element in many different biological processes. It has been established as being produced in response to many pathological states and is now referred to as a stress-related hormone. Regarding kidney functions, GDF15 has been involved in different pathologies such as chronic kidney disease, diabetic nephropathy, renal cancer, and so on. Interestingly, recent studies also revealed a role of GDF15 in the renal homeostatic mechanisms allowing to maintain constant, as far as possible, the plasma parameters such as pH and K+ values. In this review, we recapitulate the role of GDF15 in physiological and pathological context by focusing our interest on its renal effect. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.